Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
ppublish
Résumé
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 (
Identifiants
pubmed: 35977025
doi: 10.1126/sciadv.abo2341
pmc: PMC9385148
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
eabo2341Références
Mol Immunol. 2003 Jan;39(10):557-66
pubmed: 12431389
Immunotargets Ther. 2021 Jul 26;10:273-284
pubmed: 34345614
J Clin Invest. 2020 Nov 2;130(11):6151-6157
pubmed: 32759504
J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1099-1111.e6
pubmed: 33529719
Cell Death Differ. 2021 Nov;28(11):3125-3139
pubmed: 34031543
Intern Emerg Med. 2022 Apr;17(3):665-673
pubmed: 34637082
Clin Immunol. 2020 Nov;220:108598
pubmed: 32961333
JCI Insight. 2022 May 9;7(9):
pubmed: 35349483
Nature. 2021 Jul;595(7866):283-288
pubmed: 34010947
J Allergy Clin Immunol. 2020 Jul;146(1):215-217
pubmed: 32417135
Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975
pubmed: 34513750
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
Eur J Clin Invest. 2020 Oct;50(10):e13319
pubmed: 32535894
J Clin Lab Anal. 2022 Jan;36(1):e24064
pubmed: 34783405
J Immunol. 2010 Nov 1;185(9):5628-36
pubmed: 20870944
Cell Rep Med. 2021 Jun 15;2(6):100321
pubmed: 34075365
Nat Med. 2020 Oct;26(10):1609-1615
pubmed: 32747830
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Eur J Clin Invest. 2015 Apr;45(4):423-40
pubmed: 25678219
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32554923
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
EBioMedicine. 2016 Feb 06;5:175-82
pubmed: 27077125
J Infect Dis. 2021 Feb 3;223(2):214-224
pubmed: 33038254
Immunobiology. 2013 Apr;218(4):496-505
pubmed: 22795972
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
Sci Immunol. 2021 May 13;6(59):
pubmed: 34446527
Sci Immunol. 2021 Apr 7;6(58):
pubmed: 33827897
Cell. 2022 Feb 3;185(3):493-512.e25
pubmed: 35032429
J Innate Immun. 2018;10(2):94-105
pubmed: 29237166
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025
pubmed: 32943538
Lancet Rheumatol. 2020 Dec;2(12):e764-e773
pubmed: 33015643
BMJ Open. 2020 Oct 10;10(10):e043651
pubmed: 33040020
Crit Care Explor. 2021 Jan 22;3(1):e0329
pubmed: 33521646
Clin Immunol. 2018 Dec;197:96-106
pubmed: 30217791
Front Immunol. 2021 Feb 22;12:627579
pubmed: 33692801
Semin Thromb Hemost. 2022 Feb;48(1):100-108
pubmed: 34388842
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Nature. 2020 Dec;588(7836):146-150
pubmed: 32726800
EClinicalMedicine. 2020 Dec;29:100639
pubmed: 33251499
EClinicalMedicine. 2020 Nov;28:100590
pubmed: 33173853
J Glob Antimicrob Resist. 2020 Dec;23:290-291
pubmed: 33130024
J Immunol. 2000 Sep 1;165(5):2491-9
pubmed: 10946275
J Hosp Infect. 2021 Jan;107:95-97
pubmed: 33217490
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr;5(2):388-402
pubmed: 33585800
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 15;1041-1042:19-26
pubmed: 27992787
J Infect Dev Ctries. 2021 Mar 31;15(3):353-359
pubmed: 33839709
Blood. 2021 Jan 28;137(4):443-455
pubmed: 33507296
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Viruses. 2022 Jan 28;14(2):
pubmed: 35215869
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
J Clin Invest. 2021 Dec 1;131(23):
pubmed: 34618684
Nat Med. 2006 Jun;12(6):682-7
pubmed: 16715088